Departments of Anaesthesia, Montreal General Hospital. McGill University Health Centre, Montreal, Quebec, Canada.
Br J Surg. 2015 May;102(6):577-89. doi: 10.1002/bjs.9747. Epub 2015 Mar 11.
Intraoperative goal-directed therapy (GDT) was introduced to titrate intravenous fluids, with or without inotropic drugs, based on objective measures of hypovolaemia and cardiac output measurements to improve organ perfusion. This meta-analysis aimed to determine the effect of GDT on the recovery of bowel function after abdominal surgery.
MEDLINE, Embase, the Cochrane Library and PubMed databases were searched for randomized clinical trials and cohort studies, from January 1989 to June 2013, that compared patients who did, or did not, receive intraoperative GDT, and reported outcomes on the recovery of bowel function. Time to first flatus and first bowel motion, time to tolerate oral diet, postoperative nausea and vomiting, and primary postoperative ileus were included.
Thirteen trials with 1399 patients were included in the analysis. GDT shortened the time to the first bowel motion (weighted mean difference (WMD -0·67, 95 per cent c.i. -1·23 to -0·11; P = 0·020) and time to tolerate oral intake (WMD -0·95, -1·81 to -0·10; P = 0·030), and reduced postoperative nausea and vomiting (risk difference -0·15, -0·26 to -0·03; P = 0·010). When only high-quality studies were included, GDT reduced only the time to tolerate oral intake (WMD -1·18, -2·03 to -0·33; P = 0·006). GDT was more effective outside enhanced recovery programmes and in patients undergoing colorectal surgery.
GDT facilitated the recovery of bowel function, particularly in patients not treated within enhanced recovery programmes and in those undergoing colorectal operations.
术中目标导向治疗(GDT)旨在通过测量血容量不足和心输出量的客观指标以及使用血管活性药物来滴定静脉输液,以改善器官灌注。本荟萃分析旨在确定 GDT 对腹部手术后肠功能恢复的影响。
从 1989 年 1 月至 2013 年 6 月,我们检索了 MEDLINE、Embase、Cochrane 图书馆和 PubMed 数据库,纳入了比较术中接受或未接受 GDT 的患者,并报告肠功能恢复结果的随机临床试验和队列研究。纳入指标包括首次排气时间、首次排便时间、开始经口进食时间、术后恶心呕吐和原发性术后肠梗阻。
纳入的 13 项试验共 1399 例患者。GDT 缩短了首次排便时间(加权均数差(WMD)-0.67,95%可信区间(CI)-1.23 至-0.11;P=0.020)和开始经口进食时间(WMD-0.95,-1.81 至-0.10;P=0.030),并减少了术后恶心呕吐(风险差异-0.15,-0.26 至-0.03;P=0.010)。仅纳入高质量研究时,GDT 仅缩短了开始经口进食时间(WMD-1.18,-2.03 至-0.33;P=0.006)。GDT 在强化康复方案之外和结直肠手术中更有效。
GDT 促进了肠功能的恢复,特别是在未接受强化康复方案治疗的患者和接受结直肠手术的患者中。